Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines

Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth SwisherShaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Susan Darlow

Research output: Contribution to journalReview articlepeer-review

392 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/ or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this